



RCE *zhu*

PTO/SB/30 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

| | |
|------------------------|-----------------|
| Application Number | 09/815,944 |
| Filing Date | 3/22/01 |
| First Named Inventor | ALLEN |
| Art Unit | 1636 |
| Examiner Name | Qian, Celine X. |
| Attorney Docket Number | R-654 |

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

ii. ☐ Other _____

b. ☒ Enclosed

i. ☒ Amendment/Reply

iii. ☐ Information Disclosure Statement (IDS)

ii. ☒ Affidavit(s)/Declaration(s)

iv. ☒ Other Change Atty Address, Transmittal, Postcard

2. **Miscellaneous**

a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

b. ☐ Other _____

3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to

Deposit Account No. 502775

i. ☒ RCE fee required under 37 CFR 1.17(e) 04/18/2005 EFLORES 00000055 502775 09815944

ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17) 01 FC:2801 395.00 DA

iii. ☐ Other _____

b. ☐ Check in the amount of \$ _____ enclosed

c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print / Type) John E. Burke

Registration No. (Attorney / Agent) 35,836

Signature *JB*

Date April 13, 2005

CERTIFICATE OF MAILING OR TRANSMISSION

Express

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print / Type) Sandra Lee Bourassa, PLS

Signature *Sandra Lee Bourassa*

Date April 13, 2005

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

S/N 09/815,944

Application No. 09/815,944

PATENT

Confirmation No. 8251



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-------------|---|-----------------|--------------------|
| Applicant: | Allen et al. | Examiner: | Qian, Celine X. |
| Serial No.: | 09/815,944 | Group Art Unit: | 1636 |
| Filed: | March 22, 2001 | Docket No.: | R-654/40338.30USU1 |
| Title: | Transgenic Mice Containing Melanocyte Stimulating Hormone Receptor Gene Disruptions | | |

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EH943078925US

Date of Deposit: April 13, 2005

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450.

By: *Sandra Lee Bourassa*
Name: Sandra Lee Bourassa, PLS

AMENDMENT UNDER 37 C.F.R. § 1.116 ACCOMPANYING
A REQUEST FOR CONTINUED EXAMINATION UNDER 37 C.F.R. §1.114

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Office Action of January 13, 2005, Applicants timely submit the following Amendment. Entry of this Amendment and reconsideration of the claims is respectfully requested.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 4 of this paper.